Supercharged immune cells take on advanced kidney and bladder tumors
NCT ID NCT06318871
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new immune therapy for people with advanced kidney or bladder cancer. Researchers take a person's own natural killer cells, train them in the lab to better recognize cancer, and give them back along with a protein that boosts immune activity. The main goal is to see if this approach is safe and possible to do in just 5 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHROMOPHOBE RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?